Manages manifestations of psychotic disorders. ANDA 40146, held by Pharm Assoc. Fluphenazine Hydrochloride.
As of Nov 16, 2026, ANDA 40146 (Fluphenazine Hydrochloride), held by Pharm Assoc, was first approved by FDA on Aug 21, 1996, with 5 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Fluphenazine hydrochloride elixir is indicated in the management of manifestations of psychotic disorders. Fluphenazine hydrochloride has not been shown effective in the management of behavioral complications in patients with mental retardation.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 21, 1996 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fluphenazine Hydrochloride2.5MG/5ML · elixir;oral | Fluphenazine Hydrochloride | Rx |
| Jan 22, 2025 | Supplement 13Labeling · Standard review | Approved | None posted |
| Feb 23, 2017 | Supplement 5Labeling · Standard review | Approved | None posted |
| Dec 3, 2010 | Supplement 4Labeling | Approved | None posted |
| Dec 3, 2009 | Supplement 3Labeling | Approved | None posted |
| Mar 12, 2009 | Supplement 2Labeling | Approved | None posted |
| Aug 21, 1996 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters